268 related articles for article (PubMed ID: 17242697)
1. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Temmink OH; Hoebe EK; Fukushima M; Peters GJ
Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
[TBL] [Abstract][Full Text] [Related]
3. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
[TBL] [Abstract][Full Text] [Related]
5. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
6. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells.
Bijnsdorp IV; Peters GJ; Temmink OH; Fukushima M; Kruyt FA
Int J Cancer; 2010 May; 126(10):2457-68. PubMed ID: 19816940
[TBL] [Abstract][Full Text] [Related]
7. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
[TBL] [Abstract][Full Text] [Related]
8. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Bijnsdorp IV; Kruyt FA; Fukushima M; Smid K; Gokoel S; Peters GJ
Cancer Sci; 2010 Feb; 101(2):440-7. PubMed ID: 19886911
[TBL] [Abstract][Full Text] [Related]
10. Trifluorothymidine induces cell death independently of p53.
Bijnsdorp IV; Kruyt FA; Fukushima M; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):699-703. PubMed ID: 18600528
[TBL] [Abstract][Full Text] [Related]
11. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
12. Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2.
Temmink OH; Bijnsdorp IV; Prins HJ; Losekoot N; Adema AD; Smid K; Honeywell RJ; Ylstra B; Eijk PP; Fukushima M; Peters GJ
Mol Cancer Ther; 2010 Apr; 9(4):1047-57. PubMed ID: 20371715
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells.
Wang Z; Liang X; Cheng Z; Xu Y; Yin P; Zhu H; Li Q; Qian X; Liu J
Anticancer Drugs; 2013 Apr; 24(4):355-65. PubMed ID: 23426174
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of in vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines: combination versus sequential exposure.
Failli A; Consolini R; Legitimo A; Orsini G; Romanini A; Spisni R; Castagna M; Miccoli P
J Biol Regul Homeost Agents; 2011; 25(4):575-88. PubMed ID: 22217990
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle arrest by oxaliplatin on cancer cells.
William-Faltaos S; Rouillard D; Lechat P; Bastian G
Fundam Clin Pharmacol; 2007 Apr; 21(2):165-72. PubMed ID: 17391289
[TBL] [Abstract][Full Text] [Related]
19. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
Xu JM; Azzariti A; Colucci G; Paradiso A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):442-8. PubMed ID: 13680161
[TBL] [Abstract][Full Text] [Related]
20. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Temmink OH; de Bruin M; Comijn EM; Fukushima M; Peters GJ
Anticancer Drugs; 2005 Mar; 16(3):285-92. PubMed ID: 15711180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
